echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > Successfully promote hair regrowth!

    Successfully promote hair regrowth!

    • Last Update: 2021-05-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    "Except for no hair on the head, it is everywhere!" Behind the jokes are the anxiety and unspeakable pain of countless people suffering from hair loss.


    Alopecia areata (AA) is the second highest incidence of hair loss in the world.


    Today, Eli Lilly and Incyte announced that their JAK inhibitor baricitinib has achieved positive results in the second phase 3 clinical trial BRAVE-AA1 for the treatment of patients with severe alopecia areata.


    Baritinib is an oral JAK inhibitor that has been approved by the FDA for the treatment of rheumatoid arthritis.


    In the randomized, double-blind, placebo-controlled clinical trial BRAVE-AA1, the proportion of adult patients with severe alopecia who received baritinib (dose 4 mg) for 36 weeks after reaching a scalp hair coverage rate of more than 80% was 35%, significantly better than the placebo group (5%).


    These data are consistent with the results of the Phase 3 clinical trial BRAVE-AA2 announced earlier this year.


    Reference materials:

    Reference materials:

    [1] Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study Retrieved April 20, 2020, https://investor.


    [1] Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study Retrieved April 20, 2020, https://investor.


    [2] Have you caught the trouble of "bald"? Retrieved December 27, 2020, from

    [3] Olamiju et al.


    Note: This article aims to introduce the progress of medical and health research, not to recommend treatment options.


    ▽ attention [drug Mingkang Germany ] micro-channel public number

    [Medical attention Mingkang Germany ] ] micro-channel public number

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.